Premium
Transforming Regulatory Science 2012: Making a Difference
Author(s) -
Goodman J L
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.329
Subject(s) - regulatory science , excellence , food and drug administration , product (mathematics) , translational science , drug development , clinical pharmacology , business , political science , engineering ethics , pharmacology , medicine , drug , sociology , engineering , law , social science , geometry , mathematics , pathology
“What does not change is the will to change.” —Charles Olson, “The Kingfishers” The world is in the midst of scientific revolutions that can transform medicine and public health. Yet translation to needed products remains slow and expensive. There are major opportunities for new regulatory science to help transform product development and evaluation. A plan by the US Food and Drug Administration (FDA), “Advancing Regulatory Science,” identifies eight priorities and numerous actions to help catalyze transformation. Scientific excellence and collaboration, including public and private sectors, are essential for change that benefits health and economies globally. Clinical Pharmacology & Therapeutics (2012); 91 3, 375–377. doi: 10.1038/clpt.2011.329